- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01227785
Next Generation INCEPTA Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy (CRT-D) Field Following Study (NOTICE-HF)
Next Generation INCEPTA ICD and CRT-D Field Following Study: Respiratory Rate Trend Evaluation in Heart Failure (HF) Patients
This study has 2 purposes:
The first purpose of the study is to test a new family of Boston Scientific Implantable Cardioverter Defibrillators ("ICDs") and cardiac resynchronization therapy ICDs ("CRT-Ds") and show how well these new devices work in patients. This new family is called the INCEPTA ICD and the INCEPTA CRT-D.
The second purpose of the study is to collect data from a feature that monitors breathing. It is called the Respiratory Rate Trend (RRT). These data will help to better understand how changes in breathing relate to changes in clinical conditions.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Purpose
Study purpose I:
To evaluate and document appropriate clinical performance of the INCEPTA (DR and VR) implantable cardioverter defibrillator (ICD) system and the INCEPTA cardiac resynchronization therapy ICD (CRT-D) system and associated application software.
Study purpose II:
Demonstrate the clinical relevance of chronic ambulatory daily median Respiratory Rate Trend (RRT) in HF patients
Study Device
- INCEPTA (DR and VR) implantable cardioverter defibrillator (ICD) system (Models F160, F161, F162, F163)
- INCEPTA cardiac resynchronization therapy ICD (CRT-D) system (Models P162, P163, P165)
Indication ICD / CRT-D Indication according to standard clinical practice
Study Objectives
The study has two primary objectives, linked to the respective study purposes:
For purpose I:
The objective is to collect data on the clinical performance of the INCEPTA ICD and CRT-D devices during standard clinical use at implant, pre-discharge and at a 1-month post-implant. Clinical performance included analysis of pacing thresholds, pacing impedance, sensing thresholds, number of successfully converted VT/VF episodes, induced episodes detection times, spontaneous episodes, wanded telemetry, adverse events (AEs) and product experiences.
For purpose II:
The objective is to show that daily median respiratory rate increases more in patients who experience an HF-event (Group 1) than in patients who do not experience an HF-event (Group 2).
This is a prospective, multi-centre, field following study.
Up to 35 study centers in the International geography will enrol 120 patients.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
- Deutsches Herzzentrum Berlin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who are willing and capable of providing informed consent, undergoing a device implant, participating in all testing associated with this clinical study;
- Patients whose age is 18 or above, or of legal age to give informed consent specific to national law
Patients indicated for an ICD according to normal clinical practice (for those patients receiving an INCEPTA ICD).
-As soon as 20 ICD patients are included in the study for purpose I, only NYHA Class III patients will be allowed in the study.
- New York Heart Association (NYHA) Class III patients indicated for a CRT-D according to normal clinical practice (for those patients receiving an INCEPTA CRT-D).
Exclusion Criteria:
- Women of childbearing potential who are or might be pregnant at the time of the study (method of assessment upon physician's discretion)
- Enrolled in any other concurrent study.
- Inability or refusal to comply with the follow-up schedule
- Patients that have received routinely scheduled intravenous inotropic therapy as part of their drug regimen within the past 90 days
- Patients prescribed to positive airway pressure therapy
- A life expectancy of less than 1 year, per physician discretion
- Patient in NYHA Class IV during the last 4 weeks
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
INCEPTA ICD and CRT-D
ICD and CRT-D indicated patients were included in the study.
Overall patient population, CRT-D or ICD populations, and patients experiencing or not experiencing a protocol-defined heart failure event were included (dependent on outcomes measured).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Performance for Left Ventricular (LV) Sensing Amplitude at Implant for CRT-D Patients
Time Frame: implant
|
Left Ventricular (LV) Sensed Amplitude results were reported at implant for CRT-D patients.
|
implant
|
|
Clinical Performance at Pre-discharge for LV Sensing Amplitude for CRT-D Patients
Time Frame: pre-discharge
|
Left Ventricular (LV) Sensed Amplitude results were reported pre-discharge for CRT-D patients.
|
pre-discharge
|
|
Clinical Performance at1-month for Left Ventricular (LV) Sensing Amplitude for CRT-D Patients
Time Frame: 1-month
|
LV Sensed Amplitude results were reported at 1-month post-implant for CRT-D patients.
|
1-month
|
|
Clinical Performance at Implant for Right Atrium (RA) Sensing Amplitude
Time Frame: implant
|
RA Sensed Amplitude results were reported for implant for CRT-D and ICD patients
|
implant
|
|
Clinical Performance at Pre-discharge for RA Sensing Amplitude
Time Frame: pre-discharge
|
RA Sensed Amplitude results were reported at pre-discharge for CRT-D and ICD patients
|
pre-discharge
|
|
Clinical Performance at1-month for RA Sensing Amplitude
Time Frame: 1-month
|
RA Sensed Amplitude results were reported at 1-month post-implant for CRT-D and ICD patients
|
1-month
|
|
Clinical Performance at Implant for Right Ventricle (RV) Sensing Amplitude
Time Frame: implant
|
RV Sensed Amplitude results were reported at implant for CRT-D and ICD patients
|
implant
|
|
Clinical Performance at Pre-discharge for Right Ventricle (RV) Sensing Amplitude
Time Frame: pre-discharge
|
RV Sensed Amplitude results were reported at pre-discharge for CRT-D and ICD patients
|
pre-discharge
|
|
Clinical Performance at1-month for Right Ventricle (RV) Sensing Amplitude
Time Frame: 1month
|
RV Sensed Amplitude results were reported at 1-month post-implant for CRT-D and ICD patients
|
1month
|
|
Clinical Performance at Implant for LV Pacing Threshold
Time Frame: implant
|
LV pacing threshold results were reported for CRT-D patients at implant.
|
implant
|
|
Clinical Performance at Pre-discharge for LV Pacing Threshold
Time Frame: pre-discharge
|
LV pacing threshold results were reported at pre-discharge for CRT-D patients.
|
pre-discharge
|
|
Clinical Performance at1-month for LV Pacing Threshold
Time Frame: 1-month
|
LV pacing threshold results were reported at 1-month post-implant for CRT-D patients.
|
1-month
|
|
Clinical Performance at Implant for RV Pacing Threshold
Time Frame: implant
|
RV pacing threshold results were reported at implant
|
implant
|
|
Clinical Performance at Pre-discharge for RV Pacing Threshold
Time Frame: pre-discharge
|
RV pacing threshold results were reported at pre-discharge
|
pre-discharge
|
|
Clinical Performance at 1-month for RV Pacing Threshold
Time Frame: 1-month
|
RV pacing threshold results were reported at 1-month post-implant
|
1-month
|
|
Clinical Performance at Implant for RA Pacing Threshold
Time Frame: implant
|
RA pacing threshold results were reported for implant
|
implant
|
|
Clinical Performance at Pre-discharge for RA Pacing Threshold
Time Frame: pre-discharge
|
RA pacing threshold results were reported at pre-discharge
|
pre-discharge
|
|
Clinical Performance at 1-month for RA Pacing Threshold
Time Frame: 1-month
|
RA pacing threshold results were reported at 1-month post-implant
|
1-month
|
|
Clinical Performance at Implant LV Pacing Impedance for CRT-D.
Time Frame: implant
|
LV pacing impedance results at implant were measured in CRT-D.
|
implant
|
|
Clinical Performance at Pre-discharge for LV Pacing Impedance for CRT-D.
Time Frame: pre-discharge
|
LV pacing impedance results were reported for pre-discharge visit
|
pre-discharge
|
|
Clinical Performance at 1-month for LV Pacing Impedance for CRT-D.
Time Frame: 1-month
|
LV pacing impedance results were reported at 1-month post-implant
|
1-month
|
|
Clinical Performance at Implant for RV Pacing Impedance
Time Frame: implant
|
RV pacing impedance results were reported at implant
|
implant
|
|
Clinical Performance at Pre-discharge for RV Pacing Impedance
Time Frame: pre-discharge
|
RV pacing impedance results were reported for pre-discharge
|
pre-discharge
|
|
Clinical Performance at 1-month for RV Pacing Impedance
Time Frame: 1-month
|
RV pacing impedance results were reported at 1-month post-implant
|
1-month
|
|
Clinical Performance at Implant for RA Pacing Impedance
Time Frame: implant
|
RA pacing impedance results were reported at implant
|
implant
|
|
Clinical Performance at Pre-discharge for RA Pacing Impedance
Time Frame: pre-discharge
|
RA pacing impedance results were reported at pre-discharge
|
pre-discharge
|
|
Clinical Performance at 1-month for RA Pacing Impedance
Time Frame: 1-month
|
RA pacing impedance results were reported at 1-month post-implant
|
1-month
|
|
Product Experiences Reported by the Site for All Patients for Study Duration
Time Frame: Overall study results
|
Product experiences reported may include the shock impedance noise display, problems encountered with the universal serial bus (USB), a program parameter mismatch, reverse mode switches, electrogram (EGM) noise without oversensing, lead connection issues, or customer device feedback.
|
Overall study results
|
|
Induced Ventricular Tachycardia / Ventricular Fibrillation (VT/VF) Episode Successful Conversion Rates at Implant
Time Frame: implant
|
The % of successful conversions after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients.
All episodes of induced VT/VF that resolved with successful conversion were counted from the total attempted conversions and reported as the % of successful conversions from those attempted.
|
implant
|
|
Induced VT/VF Episode Successful Conversion Rates at 1-month
Time Frame: 1-month
|
The % of successful conversions after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients.
All episodes of induced VT/VF that resolved with successful conversion were counted from the total attempted conversions and reported as the % of successful conversions from those attempted.
|
1-month
|
|
Induced VT/VF Episode Successful Conversion Rates at 3-months
Time Frame: 3-month
|
The % of successful conversions after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients.
All episodes of induced VT/VF that resolved with successful conversion were counted from the total attempted conversions and reported as the % of successful conversions from those attempted.
|
3-month
|
|
Induced Episode Detection Times at Implant
Time Frame: implant
|
The mean time it took to complete a successful conversion after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients.
The time was recorded (in seconds) for the time duration that was required to successfully convert the patient after inducing VT/VF.
|
implant
|
|
Induced Episode Detection Times at 1-month
Time Frame: 1-month
|
The mean time it took to complete a successful conversion after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients.
The time was recorded (in seconds) for the time duration that was required to successfully convert the patient after inducing VT/VF.
|
1-month
|
|
Induced Episode Detection Times at 3 Months
Time Frame: 3-month
|
The mean time it took to complete a successful conversion after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients.
The time was recorded (in seconds) for the time duration that was required to successfully convert the patient after inducing VT/VF.
|
3-month
|
|
Spontaneous Episode Conversion Success Rate at 3 Months
Time Frame: 3-month
|
Of the total patients that experienced a spontaneous episode, the % of patients with a spontaneous rhythm conversion that was successful was determined.
|
3-month
|
|
Wanded Telemetry Issues at Pre-discharge Follow-up
Time Frame: Pre-Discharge visit occurred after implant but prior to 1 month follow-up visit
|
The Investigators completed a questionnaire based on the performance of the wanded telemetry during device interrogations at pre-discharge follow-up.
The number of problems reported were counted from the entire study cohort.
|
Pre-Discharge visit occurred after implant but prior to 1 month follow-up visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate the Daily Median Respiratory Rate Trend in Patients Who Experience a HF-event Compared to Patients Who do Not Experience a HF-event.
Time Frame: Results were captured from implant time window to the first event for patients with HFE, up to an average of 9 months
|
A comparison of the change in respiratory rate trend over time was made between patients who experienced a protocol-defined HF event (HFE) (Group1: Patients with a HFE) and patients who did not experience a protocol-defined heart failure event (Group 2: Patients without a HFE).
Only patients with at least 3 valid daily respiratory rate values (60%) out of each 5-day window were evaluated.
The objective was to show that daily median respiratory rate increases more in patients who experience a HFE (Group 1) than in patients who do not experience an HFE (Group 2).
A comparison between patients who experience a HFE (Group 1) and patients who do not experience a HFE (Group 2).
Two average daily median respiratory rates were done per patient: 60 to 56 days before an index time and 11 to 7 days before the same index time; the difference between these two averaged daily median respiratory rates was done.
Index time=day of the first HFE (Group 1) and day of 6-month visit (Group 2).
|
Results were captured from implant time window to the first event for patients with HFE, up to an average of 9 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NOTICE-HF 0410
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Indiana UniversityRecruitingCongestive Heart Failure | Congestive Heart Failure (CHF) | Congestive Heart Failure Chronic | Congestive Heart Failure(CHF)United States
-
University of Health Sciences LahoreRecruitingAcute Decompensated Heart Failure | Heart Failure, Diastolic | Heart Failure, SystolicPakistan
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
Lakeland Regional Health Systems, Inc.RecruitingHeart Failure | Heart Failure Acute | Acute Heart Failure (AHF) | Heart Failure - NYHA II - IVUnited States
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Eli Lilly and CompanyNot yet recruitingHeart Failure | Heart Failure, Diastolic | Heart Failure, SystolicUnited States, Japan
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
Clinical Trials on INCEPTA ICD or CRT-D
-
Biotronik Australia Pty Ltd.Biotronik SE & Co. KGActive, not recruitingHeart Failure | TachycardiaAustralia
-
Biotronik SE & Co. KGNot yet recruitingHeart Failure | Tachyarrhythmia
-
Medtronic Cardiac Rhythm and Heart FailureCompletedVentricular Arrythmia | Sudden Cardiac ArrestChina, Korea, Republic of, Taiwan, Argentina, Colombia, Singapore, Russian Federation, India, South Africa, Malaysia, United Arab Emirates, Belarus, Brazil, Egypt, Mexico, Tunisia
-
Medtronic Cardiac Rhythm and Heart FailureCompletedHeart Failure | Ventricular Dysfunction | TachyarrhythmiasUnited States, Netherlands, Colombia, South Africa, Japan, Israel, Spain, Canada, United Kingdom, Germany, Slovenia, Sweden, Saudi Arabia, Switzerland, Malaysia, Austria, Czechia, Denmark, India, Italy, United Arab Emirates
-
Abbott Medical DevicesWithdrawn
-
Biotronik SE & Co. KGCompletedVentricular Fibrillation | Ventricular Tachycardia | Congestive Heart FailureDenmark, Germany, Israel, Australia, Austria, Czech Republic, Latvia
-
Abbott Medical DevicesCompleted
-
Biotronik Japan, Inc.CompletedHeart Failure | Arrhythmias, CardiacJapan
-
Abbott Medical DevicesCompletedSudden Cardiac DeathUnited States
-
LivaNovaCompletedSleep ApnoeaFrance, Italy, Germany, Greece